Pricing Strategies and Reimbursement

 The US off-patent association published an analysis of IQVIA data, which highlights the role of rebate schemes that is slowing the adoption of Humira biosimilars that would save billions of dollars.

The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.

Price increases from multiple suppliers pushed vardenafil to the top of our Biggest Risers table for March 2024.

Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.

US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.

Boehringer Ingelheim’s decision to cut sales staff for its Cyltezo US biosimilar rival to Humira not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the struggles for Humira biosimilars more widely.

If Outlook Therapeutics’ Lytenava secures EU approval for wet AMD, the company says it expects to price the drug as a lower cost alternative to biosimilars and premium branded products for the condition, and higher than off-label compounds.

A raft of different generics saw their average UK trade price more than double in February 2024, according to the latest figures from market researcher WaveData.

Ahead of a planned September UN meeting, the industry group and key companies demand concrete steps that could turn the tide in the fight against antimicrobial resistance.

UK competition watchdog the CMA has announced that it will be appealing against a tribunal decision that has overturned nearly £100m of fines imposed over anti-competitive deals around hydrocortisone, based on what the CMA criticized as a “fundamentally misconceived procedural point” linked to the cross-examination of witnesses.

Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.

Sandoz has agreed a $265m settlement in the US to resolve generic pricing antitrust class action litigation with direct purchaser plaintiffs, as part of a deal that contains no admission of wrongdoing on the part of the generics giant.

Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

The AAM’s annual Access! 2024 conference brought its much-enjoyed CEOs Unplugged panel to Tampa again for another engaging discussion on critical issues, challenges and opportunities for generics and biosimilars in the US.

The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.